Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Kira8 (AMG-18) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity (IC50: 5.9 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 89.00 | |
5 mg | In stock | $ 213.00 | |
10 mg | In stock | $ 322.00 | |
25 mg | In stock | $ 597.00 | |
50 mg | In stock | $ 852.00 | |
100 mg | In stock | $ 1,170.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 283.00 |
Description | Kira8 (AMG-18) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity (IC50: 5.9 nM). |
Targets&IC50 | IRE1α:5.9 nM(IRE1α RNase) |
In vitro | Kira8 more effectively causes IRE1α-driven apoptosis in INS-1 cells than KIRA6 and also reverses XBP1 splicing promoted by GNF-2. Kira8 blocks IRE1α oligomerization and effectively inhibits IRE1α RNase activity against XBP1 and Ins2 RNAs. |
In vivo | One week of treatment of pre-diabetic NODs mice with Kira8 (50 mg/kg; i.p.; once a day) causes obvious reductions in islet XBP1 splicing and TXNIP mRNAs. It also preserves Ins1/Ins2, BiP, and MANF mRNAs. Male Ins2+/Akita mice are injected i.p. with KIRA8 (50 mg/kg; daily; for 35 days), obviously reduction of hyperglycemia becomes apparent over several weeks. |
Synonyms | AMG-18 |
Molecular Weight | 601.12 |
Formula | C31H29ClN6O3S |
CAS No. | 1630086-20-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 65 mg/mL (108.13 mM), sonification is recommended.
H2O: insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Kira8 1630086-20-2 Cell Cycle/Checkpoint IRE1 Inositol requiring enzyme 1 inhibit AMG-18 Kira 8 Inhibitor Kira-8 AMG 18 AMG18 inhibitor